#1 Source in Thailand
Active since 2012
Jintrolong 9mg/54iu

Jintrolong 9mg/54iu

16,500฿

The Jintrolong comes with a reusable pen.

Jintrolong (generic name: Recombinant Human Growth Hormone, rhGH) is a biosynthetic human growth hormone manufactured by Gensci Pharmaceutical Co., Ltd., a leading biopharmaceutical company in China.

It is identical in structure to the naturally occurring pituitary growth hormone and is used to treat conditions caused by growth hormone deficiency or insufficiency.

Here are the key benefits of Jintrolong by Gensci, categorized for clarity:

1. Primary Therapeutic Benefits (For Approved Indications)

  • In Children:

    • Promotes Linear Growth: The primary benefit for children with Growth Hormone Deficiency (GHD) is the stimulation of bone and cartilage growth, leading to increased height and improved height velocity, helping them reach a more normal adult height.

    • Improves Body Composition: Increases muscle mass and reduces body fat percentage.

    • Enhances Bone Mineral Density: Strengthens bones, which is crucial for long-term skeletal health.

    • Boosts Energy and Strength: Children often report improved physical energy and exercise capacity.

  • In Adults:

    • Restores Body Composition: Significantly reduces adipose tissue (especially abdominal fat), increases lean body mass (muscle), and improves muscle strength and exercise tolerance.

    • Improves Metabolic Profile: Enhances insulin sensitivity, improves lipid metabolism (can lower “bad” LDL cholesterol and increase “good” HDL cholesterol), and supports cardiovascular health.

    • Enhances Quality of Life: Addresses the debilitating symptoms of adult GHD, including chronic fatigue, low energy, reduced stamina, emotional distress, social isolation, and impaired cognitive function (e.g., poor memory and concentration).

    • Increases Bone Density: Reduces the risk of osteoporosis and fractures in adults with GHD.

2. Benefits Specific to the Jintrolong Product & Gensci

  • High Purity and Quality: As a recombinant DNA technology product, it eliminates the risks associated with older pituitary-derived GH (like Creutzfeldt-Jakob disease). Gensci manufactures it to high international standards.

  • Liquid Formulation (Key Advantage): Jintrolong is presented as a ready-to-use liquid cartridge (in devices like the Jintropin AQ pen). This offers significant benefits over traditional powdered (lyophilized) growth hormone:

    • Convenience: No need for reconstitution (mixing with water), saving time and reducing preparation errors.

    • Improved Accuracy: Eliminates the risk of incorrect dilution.

    • Enhanced Stability: The liquid formulation is designed to be stable at 2-8°C for its shelf life.

    • Reduced Pain: Some patients report less injection discomfort compared to reconstituted products.

  • Delivery System: Gensci offers pen devices (like the Jintropin AQ Pen) for administering Jintrolong. These pens are designed to be:

    • User-Friendly: Easy to use, especially for daily injections at home.

    • Discreet: Pen designs are often compact.

    • Dose-Accurate: Allows for precise dose setting, which is critical for safety and efficacy.

  • Established Manufacturer: Gensci is a well-known and long-standing company in the field of endocrinology in Asia, providing a sense of reliability and having extensive clinical experience with its product.

  • Potential Side Effects: Benefits must be weighed against potential risks, which can include fluid retention (edema, joint pain), insulin resistance, carpal tunnel syndrome, and, very rarely, increased intracranial pressure. Long-term safety is monitored by a physician.

  • Requires Medical Supervision: Treatment requires diagnosis through stimulation tests and ongoing monitoring by an endocrinologist (including IGF-1 levels, blood glucose, thyroid function, and spine exams for scoliosis in children).

Summary of Key Benefits:

For the Patient: Effectively treats growth hormone deficiency, leading to improved growth (in children), better body composition, enhanced metabolism, and a higher quality of life.

For the User: The ready-to-use liquid formulation in a pen device offers major advantages in terms of convenience, accuracy, stability, and ease of administration compared to traditional powdered GH.

Crucial Disclaimer: This information is for educational purposes only. The use of Jintrolong must be under the guidance and prescription of a qualified healthcare professional who can evaluate the individual’s specific medical condition, potential benefits, and risks.

Category:

Description

Jintrolong 9mg/54iu box


 

Jintrolong (generic name: recombinant human growth hormone, rhGH) is a biosynthetic human growth hormone (somatropin) manufactured by Gensci Pharmaceutical Co., Ltd., a leading biopharmaceutical company in China. It is used to treat growth disorders in children and hormone deficiency in adults.

Effects and Medical Uses

Jintrolong is identical to the growth hormone naturally produced by the human pituitary gland. Its effects are mediated by stimulating growth, cell reproduction, and regeneration.

Primary Approved Uses:

  1. Growth Hormone Deficiency (GHD) in Children: The primary use. It promotes linear growth, increases height, and improves bone density in children diagnosed with GHD.

  2. Turner Syndrome: In girls with this genetic condition, it helps improve growth and final adult height.

  3. Chronic Renal Insufficiency (CRI) in Children: Mitigates growth failure associated with chronic kidney disease prior to transplantation.

  4. Adult Growth Hormone Deficiency (AGHD): In deficient adults, it helps:

    • Increase muscle mass and decrease body fat.

    • Improve bone density and lipid profile.

    • Enhance energy levels, exercise capacity, and overall quality of life.

Mechanism of Action: It stimulates the liver to produce insulin-like growth factor-1 (IGF-1), which is the primary mediator of growth hormone’s effects on growth and metabolism.

Administration: It is administered via daily subcutaneous injection (under the skin). Compliance with the daily regimen is crucial for efficacy.

History and Development

The history of Jintrolong is intertwined with the development of China’s biopharmaceutical industry.

  • Era of Gensci: Gensci Pharmaceutical was founded in 1997 and quickly became a pioneer in China’s rhGH market. Before companies like Gensci, China relied on imported growth hormone products, which were expensive and less accessible.

  • Domestically Developed rhGH: Jintrolong was one of the first successful domestically developed and produced recombinant human growth hormones in China. Its launch was a significant step in making this critical treatment more affordable and widely available within the country.

  • Technological Advancements: Over the years, Gensci has invested in advanced recombinant DNA technology and production processes (using E. coli expression systems) to ensure the purity, safety, and efficacy of Jintrolong, meeting both Chinese and international standards.

  • Market Position: For many years, Jintrolong has been a market leader in China’s rhGH sector, trusted by pediatric endocrinologists and patients. Gensci’s extensive educational efforts for doctors and patient support programs have contributed significantly to its widespread adoption.

Availability

The availability of Jintrolong is highly region-specific and strictly regulated due to its status as a prescription-only biologic drug.

Milo

  1. Primary Market: Mainland China

    • Widely Available: Jintrolong is extensively available and one of the most prescribed growth hormone brands in China. It is stocked in major hospital pharmacies and through authorized distributors.

    • Prescription Required: It is a Class B prescription drug in China and can only be obtained with a valid prescription from a qualified endocrinologist, following a rigorous diagnostic process (including stimulation tests for GHD).

    • Insurance Coverage: It may be partially covered by some urban medical insurance schemes in China, but coverage varies significantly by city and diagnosis. Out-of-pocket costs can still be substantial for many families.

  2. International Markets:

    • Limited Global Distribution: Jintrolong is primarily focused on the domestic Chinese market. It is not approved by major regulatory agencies like the U.S. FDA or the European EMA for sale in the United States, European Union, or the United Kingdom.

    • Some Asian and Emerging Markets: It may be registered and available in a limited number of other countries, often under different brand names or through specific partnerships. However, its presence is not global.

    • Milo-Lab is the first supplier of Jintrolong in Thailand!

Conclusion

Jintrolong, developed by Gensci, represents a major achievement in China’s pharmaceutical industry, providing a critical and effective treatment for growth hormone deficiencies. Its effects on growth and metabolism are well-established for specific medical conditions. Its history is that of a domestic brand that achieved market leadership by improving accessibility within China. Regarding availability, it is a mainstream treatment option within China under strict medical supervision but remains largely unavailable in most Western markets due to different regulatory landscapes. Any use must be guided by a specialist endocrinologist.

Reviews

There are no reviews yet.

Be the first to review “Jintrolong 9mg/54iu”

Related products

Cart0
There are no products in the cart!
Continue shopping
0